June 20-22, 2018
Boston, MA

2018 Speakers

Expand/Collapse

David Donabedian
CEO
Axial Biotherapeutics

Ravi Starzl
CEO
Bioplx

Day Two

Friday June 22, 2018

13.40 | A New Approach to Therapeutic Durability and Integration

Adrien Nivoliez
CEO
Biose

Adham Aljahami
Co-founder, CEO
Blue Turtle Bio Technologies, Inc

Day Two

Friday June 22, 2018

15.50 | Known Unknowns - An Outsiders Perspective On The Cost Of Being at The Forefront Of Biotech’s New Chapter

Jeffrey Heiser
Director Microbiology
Boston Analytical

Day Two

Friday June 22, 2018

10.30 | Application of Multivalent Vaccine Manufacturing Testing Schemes in cGMP Characterization of Microbiome Defined Drug Products

Ben Bradley
Technology Innovation Lead
CHAIN Biotechnology Ltd

Ian Parsons
Director Analytical Laboratories
Charles River Laboratories

Rana Samadfam
Scientific Director
Charles River Laboratories

Stanley Hazen
Head of Preventative Cardiology and Rehabilitation
Cleveland Clinic

Manoj Dadlani
CEO
CosmosID

Dan Knights
CEO
CoreBiome

Day Two

Friday June 22, 2018

09.00 | Powering Microbiome Discovery with Big Data

Cathryn Nagler
Bunning Food Allergy Professor, University of Chicago
President, ClostraBio

Day One

Thursday June 21, 2018

09.30 | The Gut Microbiome, Immunity and Allergic Disease

Bjorn Nielsen
Chief Scientific Officer
Clinical-Microbiomics

Day One

Thursday June 21, 2018

10.00 | What Microbiome Systems Biology Can Tell About Mechanism

Julie Cope
Director Scientific Operations
Diversigen

Day One

Thursday June 21, 2018

09.00 | Microbiome Tools & Trends for the Pharmaceutical Industry

Lisa Gamswell
Microbiome Project Manager
DNA Genotek

Xavier Duportet
CEO
Eligo Biosciences

Day Two

Friday June 22, 2018

14.20 | Using Synthetic Biology for Targeted Antimicrobials & Microbiome Engineering

Christophe Bonny
Chief Scientific Officer
Enterome Bioscience

Rodolphe Clerval
Chief Business Officer
Enterome Bioscience

Workshop B

Wednesday, June 20

11.00am | Insights into Study Design & Analysis for Commercial Success in Microbiome Product Development

Paul Carlson
Principal Investigator
FDA

Day One

Thursday June 21, 2018

16.50 | Panel Presentation – Building Clear Regulatory Guidelines for Microbiome-Based Therapeutics

16.10 | Regulatory Considerations for Live Biotherapeutic Products & Bacteriophage Therapy

Mark Smith
CEO
Finch Therapeutics Group

Kirk Taylor
Chief Medical Officer
Finch Therapeutics Group

Bharat Dixit
VP Bioprocess Development & Manufacturing
Finch Therapeutics Group

Phil Strandwitz
Co-Founder and CEO
Holobiome, Inc

Anuk Das
Head, Scientific Innovation
Janssen Human Microbiome Institute

Dan Meyers
Head of Product Development
Janssen Human Microbiome Institute

Workshop B

Wednesday, June 20

11.00am | Insights into Study Design & Analysis for Commercial Success in Microbiome Product Development

Salvatore Morello
Senior Director Global Regulatory Affairs
Janssen Pharmaceuticals

Day One

Thursday June 21, 2018

16.50 | Panel Presentation – Building Clear Regulatory Guidelines for Microbiome-Based Therapeutics

Jean Luc-Treillou
CEO
LNC Therapeutics

Les Tillack
Managing Director
Luina Bio

Alessio Fasano
Allan Walker Chair in Paediatric Gastroenterology & Nutrition
Massachusetts General Hospital

Workshop B

Wednesday, June 20

11.00am | Insights into Study Design & Analysis for Commercial Success in Microbiome Product Development

Michael Romanos
CEO
Microbiotica

Trevor Lawley
Chief Scientific Officer
Microbiotica

Day Two

Friday June 22, 2018

10.00 | Precision Discovery of Novel Biomarkers Based on Deep Microbiome Analysis

Henry Haiser
Investigator III
Novartis Institutes for BioMedical Research (NIBR)

Els van Hoffen
Project Manager Health
NIZO

Magali Cordaillat-Simmons
Scientific and Regulatory Affairs Director
PRI

Day One

Thursday June 21, 2018

16.50 | Panel Presentation – Building Clear Regulatory Guidelines for Microbiome-Based Therapeutics

16.30 | Regulatory Challenges for Registering Live Biotherapeutic Products in Europe

Massimo Marzorati
Chief Business Officer
ProDigest

Dean Scholl
Scientist
Pylum Biosciences

Day Two

Friday June 22, 2018

14.00 | Presentation Title To Be Confirmed: Please Check Back With Us Soon

Eva Berkes
Chief Scientific Officer
Quorum Innovations

Day Two

Friday June 22, 2018

15.10 | What is the Role of Biofilms in Human Microbiome Discovery?

Mike Frodsham
Pharmaceutical Development Manager
Quay Pharma

Ken Blount
Chief Scientific Officer
Rebiotix

Day Two

Friday June 22, 2018

09.30 | Using the “Microbiome Health Index” to Identify Indicators for Microbiome Restoration

Edward Burd
Head of Regulatory Affairs
Rebiotix

Day One

Thursday June 21, 2018

16.50 | Panel Presentation – Building Clear Regulatory Guidelines for Microbiome-Based Therapeutics

David Cook
EVP and Chief Scientific Officer
Seres Therapeutics

Day One

Thursday June 21, 2018

08.30 | Inflammatory Bowel Disease & Immuno-Oncology: the Prospects for Clinical Immune Modulation by Microbiome Drugs

Ward Peterson
CEO
Symberix

Day Two

Friday June 22, 2018

13.20 | Symbiotic Drugs For Good Bugs Gone Bad

Isil Tuzun Weber
Process Engineer
SynCo Bio Partners

Dick Schwartz
SVP Process Development & Manufacturing
Synlogic Therapeutics

Caroline Kurtz
Head of Translational Sciences & Product Development
Synlogic Therapeutics

Christian Furlan Freguia
Director of Research
Synthetic Biologics

Jessica Schneider
Associate Scientific Director
Takeda

Day Two

Friday June 22, 2018

08.30 | Prioritizing Indications for Microbiome Therapeutics: Where do we go after C.difficile and UC?

Natalia Palacios
Assistant Professor
UMass Lowell

Workshop A

Wednesday, June 20

08.30am | Understanding Parkinson’s Disease Through the Gut Microbiome: Possibilities for New Interventions

Rita Colwell
Distinguished University Professor
University of Maryland

Workshop B

Wednesday, June 20

11.00am | Insights into Study Design & Analysis for Commercial Success in Microbiome Product Development

Bruce Roberts
Chief Scientific Officer
Vedanta Biosciences

David Beno
Chief Scientific Officer
Xeno Biosciences

Day Two

Friday June 22, 2018

15.30 | Pharmacological Mimicry of the Gastric Bypass Microbiome to Treat Obesity